Abstract
To investigate the relation between the clinicopathological findings, and the survival of patients with malignant tumours of the maxillary sinus, and the tumour's biological parameters, we examined the expression of p53 and bcl-2 and the number of silver-stainable nucleolar organizer regions (AgNORs) in 23 paraffin-embedded specimens from primary tumours. Fifteen of 23 (65 per cent) maxillary tumours expressed p53 and two of 23 (nine per cent) tumours expressed the bcl-2 gene product. The mean number of AgNORs per nucleus was 5.2 ± 2.4. There was no relationship between the expression of p53 or bcl-2 and the patient's clinical course. In contrast, there was a statistically significant difference in the survival of patients with a high (> 6) number of AgNORs and patients with a low (< 6) number of AgNORs. These data suggest that the number of AgNORs may be useful in evaluating the prognosis of patients with malignant maxillary sinus tumours.
| Original language | English |
|---|---|
| Pages (from-to) | 38-42 |
| Number of pages | 5 |
| Journal | Journal of Laryngology and Otology |
| Volume | 111 |
| Issue number | 1 |
| Publication status | Published - Mar 5 1997 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Otorhinolaryngology
Cite this
p53 and bcl-2 expression and argyrophilic nucleolar organizer regions in patients with malignant maxillary sinus tumours. / Nakashima, Torahiko; Nakashima, Tadashi; Masuda, Muneyuki; Komiyama, Sohtaro.
In: Journal of Laryngology and Otology, Vol. 111, No. 1, 05.03.1997, p. 38-42.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - p53 and bcl-2 expression and argyrophilic nucleolar organizer regions in patients with malignant maxillary sinus tumours
AU - Nakashima, Torahiko
AU - Nakashima, Tadashi
AU - Masuda, Muneyuki
AU - Komiyama, Sohtaro
PY - 1997/3/5
Y1 - 1997/3/5
N2 - To investigate the relation between the clinicopathological findings, and the survival of patients with malignant tumours of the maxillary sinus, and the tumour's biological parameters, we examined the expression of p53 and bcl-2 and the number of silver-stainable nucleolar organizer regions (AgNORs) in 23 paraffin-embedded specimens from primary tumours. Fifteen of 23 (65 per cent) maxillary tumours expressed p53 and two of 23 (nine per cent) tumours expressed the bcl-2 gene product. The mean number of AgNORs per nucleus was 5.2 ± 2.4. There was no relationship between the expression of p53 or bcl-2 and the patient's clinical course. In contrast, there was a statistically significant difference in the survival of patients with a high (> 6) number of AgNORs and patients with a low (< 6) number of AgNORs. These data suggest that the number of AgNORs may be useful in evaluating the prognosis of patients with malignant maxillary sinus tumours.
AB - To investigate the relation between the clinicopathological findings, and the survival of patients with malignant tumours of the maxillary sinus, and the tumour's biological parameters, we examined the expression of p53 and bcl-2 and the number of silver-stainable nucleolar organizer regions (AgNORs) in 23 paraffin-embedded specimens from primary tumours. Fifteen of 23 (65 per cent) maxillary tumours expressed p53 and two of 23 (nine per cent) tumours expressed the bcl-2 gene product. The mean number of AgNORs per nucleus was 5.2 ± 2.4. There was no relationship between the expression of p53 or bcl-2 and the patient's clinical course. In contrast, there was a statistically significant difference in the survival of patients with a high (> 6) number of AgNORs and patients with a low (< 6) number of AgNORs. These data suggest that the number of AgNORs may be useful in evaluating the prognosis of patients with malignant maxillary sinus tumours.
UR - http://www.scopus.com/inward/record.url?scp=0031050798&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031050798&partnerID=8YFLogxK
M3 - Article
C2 - 9292129
AN - SCOPUS:0031050798
VL - 111
SP - 38
EP - 42
JO - Journal of Laryngology and Otology
JF - Journal of Laryngology and Otology
SN - 0022-2151
IS - 1
ER -